However, the efforts of many research groups over the past two decades has defied this view point with a number of inhibitors progressing through clinical trials which target the Bcl‐2 family (ABT‐737, navitoclax and ABT‐199).73, 83 However, despite the recent success in targeting Bcl‐2 and Bcl‐xL, the modulation of Mcl‐1 with inhibitors has proven elusive and there are currently no Mcl‐1 inhibitors in clinical trial despite the fact that Mcl‐1 is one of the most commonly amplified genes in cancer.84 The gene discussed is MCL1; the disease is cancer.